Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points

Reliability and life testing (62N05) General biostatistics (92B15)

Recommendations

Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
The validation of surrogate endpoints in meta-analyses of randomized experiments
The evaluation of surrogate endpoints.
Validation of surrogate markers in multiple randomized clinical trials with repeated measurements
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

Cited In (52)

Choice of units of analysis and modeling strategies in multilevel hierarchical models
Cluster-robust estimators for multivariate mixed-effects meta-regression
Unbalanced cluster sizes and rates of convergence in mixed-effects models for clustered data
Bayesian adaptive trial design for a newly validated surrogate endpoint
Estimation of a common mean vector in bivariate meta-analysis under the FGM copula
Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
Center-within-trial versus trial-level evaluation of surrogate endpoints
Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
Validation of surrogate markers in multiple randomized clinical trials with repeated measurements
Using surrogate failure time data to increase cost effectiveness in clinical trials
Missing data methods in longitudinal studies: a review
Generalized shared-parameter models and missingness at random
Dynamic lifetime prediction using a Weibull-based bivariate failure time model: a meta-analysis of individual-patient data
True endpoint reduction by surrogate endpoints
Incomplete multiresponse designs and surrogate endpoints in clinical trials
Confidence intervals and statistical power of the ``Validation ratio for surrogate or intermediate endpoints
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling
Confirmatory adaptive group sequential designs for single‐arm phase II studies with multiple time‐to‐event endpoints
A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials
An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
A perspective on surrogate endpoints in controlled clinical trials
Bivariate network meta-analysis for surrogate endpoint evaluation
One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints
Optimizing and evaluating biomarker combinations as trial-level general surrogates
Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's \(\tau\)
Multi-stage enrichment and basket trial designs with population selection
Estimation of treatment effect in 2-in-1 adaptive design and some of its extensions
On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
Exploring and validating surrogate endpoints in colorectal cancer
Testing for Heterogeneity in the Utility of a Surrogate Marker
surrosurv
Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach
The Evaluation of Multiple Surrogate Endpoints
The validation of surrogate endpoints in meta-analyses of randomized experiments
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
The evaluation of surrogate endpoints.
Assessing the numerical integration of dynamic prediction formulas using the exact expressions under the joint frailty-copula model
Meta-analysis of individual patient data with semi-competing risks under the Weibull joint frailty-copula model
Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles
On composite marginal likelihoods
Assessing the value of a censored surrogate outcome
Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data
Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes
Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data
Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
Simplified modeling strategies for surrogate validation with multivariate failure-time data
The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
Bayesian ridge regression for survival data based on a vine copula-based prior
Joint modeling of progression-free and overall survival and computation of correlation measures
Bayesian ridge estimators based on copula-based joint prior distributions for regression coefficients

This page was built for publication: Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q87467)